BioSpace News Archive

Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it received FDA Emergency Use Authorization (EUA) and is scaling up capacity for CRL Rapid Response™, a saliva-based COVID-19 RT-PCR test that can be self-collected at home, work or any other setting.

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today updated its total voting rights disclosure position.

Researchers led by a team at Rosalind Franklin University of Medicine and Science have devised a new therapeutic approach to treating a rare but deadly neurodegenerative genetic disease in children.

Xeris Pharmaceuticals, Inc. announced that on July 29, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 18,000 shares of its common stock to 4 new employees under Xeris’ Inducement Equity Plan.

VistaGen Therapeutics, Inc., a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system disorders, announced it has commenced an underwritten public offering of shares of its common stock.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 20 individuals hired by Sarepta in July 2020.

Monjuvi is a new treatment in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL)

The following is attributed to FDA Commissioner Stephen M. Hahn, M.D., and Susan Mayne, Ph.D., director of the Center for Food Safety and Applied Nutrition.

BIOQUAL announces the publication of the successful testing of a candidate vaccine in non-human primates.